Physician
Sylacauga Pediatric Clinic, LLC
Sylacauga Pediatric Clinic, LLC was paid $4.40M by Medicaid between Jan 2018 and Nov 2024, across 67 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 26% of everything it billed.
33Billing provider infoSYLACAUGA PEDIATRIC CLINIC, LLC
SYLACAUGA, AL 35150
SYLACAUGA, AL 35150
33aNPI1184776551assigned 01/17/2007
33bProvider typePediatrics Physician
28Total paid$4.40M
24GClaims149,971
24DCodes billed67
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Pediatrics Physician providers in Alabama
Rank by total paid#40 of 199
Median peer was paid$702K
This provider vs. median6.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,775 | $448K | |
| 2019 | 21,488 | $525K | |
| 2020 | 15,605 | $546K | |
| 2021 | 21,952 | $713K | |
| 2022 | 25,140 | $744K | |
| 2023 | 25,855 | $834K | |
| 2024incomplete | 18,156 | $589K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 26% | 14,793 | 12,952 | $1.14M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 20% | 16,682 | 14,484 | $895K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 13% | 3,091 | 2,798 | $578K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 7.3% | 12,456 | 11,463 | $322K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 6.1% | 15,122 | 13,739 | $269K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 5.1% | 18,036 | 16,699 | $224K |
| 85027 | 2.7% | 26,235 | 23,275 | $118K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 2.5% | 2,313 | 2,075 | $112K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 1.7% | 1,884 | 1,716 | $77K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.7% | 1,795 | 1,691 | $75K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.6% | 2,760 | 2,591 | $69K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.5% | 784 | 687 | $65K |
55 more codes
| 87070 | 1.1% | 4,544 | $48K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.0% | 882 | $45K |
| 87634 | <1% | 1,014 | $44K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 845 | $43K |
| 86308 | <1% | 6,031 | $33K | |
| 96132 | <1% | 354 | $25K | |
| 90461 | <1% | 534 | $24K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 471 | $22K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,394 | $22K |
| 84702 | <1% | 2,100 | $22K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 2,075 | $18K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 283 | $14K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 257 | $14K |
| 99462 | <1% | 285 | $9K | |
| 81003 | <1% | 3,166 | $8K | |
| 99460 | <1% | 157 | $8K | |
| 90686 | <1% | 611 | $6K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 444 | $6K |
| 96138 | <1% | 290 | $6K | |
| 90670 | <1% | 649 | $5K | |
| 90734 | <1% | 110 | $5K | |
| 87420 | <1% | 358 | $5K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 67 | $4K |
| 82948 | <1% | 1,076 | $4K | |
| 96101 | <1% | 70 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,563 | $3K |
| 36416 | <1% | 1,041 | $2K | |
| 90619 | <1% | 45 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 90 | $968.66 |
| 90680 | <1% | 263 | $944.00 | |
| 90633 | <1% | 176 | $943.92 | |
| 96103 | <1% | 70 | $871.71 | |
| 99464 | <1% | 14 | $858.00 | |
| 86318 | <1% | 60 | $702.00 | |
| 99173 | <1% | 263 | $610.00 | |
| 90688 | <1% | 55 | $600.48 | |
| 90677 | <1% | 102 | $576.00 | |
| 90715 | <1% | 58 | $506.35 | |
| 90698 | <1% | 161 | $456.00 | |
| 92551 | <1% | 177 | $345.00 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 29 | $314.00 |
| 96161 | <1% | 104 | $296.94 | |
| 90651 | <1% | 76 | $280.00 | |
| 90710 | <1% | 37 | $192.00 | |
| 90671 | <1% | 17 | $104.00 | |
| 90685 | <1% | 23 | $96.00 | |
| 90723 | <1% | 59 | $88.00 | |
| 90696 | <1% | 14 | $88.00 | |
| 90648 | <1% | 59 | $88.00 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 38 | $74.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 99 | $54.00 |
| 90716 | <1% | 13 | $32.00 | |
| 90707 | <1% | 13 | $32.00 | |
| 99000 | 0% | 220 | $0.00 | |
| 99401 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDARK, CYNTHIA (OFFICE MANAGER)